Manila Times Business
Key Milestone Achieved: NDA for Sumecigrel Capsule, an Antiplatelet Innovative Drug by Vcare PharmaTech, Officially Accepted
NANJING, China, June 26, 2026 /PRNewswire/ -- Recently, the NDA for Sumecigrel Capsule (formerly known as Vicagrel), a Class 1 innovative antiplatelet drug developed by Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech), has been officially accepted by the NMPA. The drug has now entered the NDA stage. As a global pioneer in novel antiplatelet agents, Sumecigrel is expected to provide a new and improved treatment option to tens of millions of patients with cardiovascular and cerebrovascular dis
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Euronext announces completion of share repurchase programme as part of its long-term incentive plan
1h ago
EDF: EDF announces the signature of an agreement to sell EDF power solutions in the United States and Canada
1h ago
FDA Proposes Rule That Would Help Hold Foreign Tobacco Product Manufacturers Accountable, Protect Public Health
1h ago
A Moroccan court sentences 29 prominent people in major drug trafficking and corruption case
1h ago